This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and
tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW)
administered subcutaneously (SC) as compared to GA 20 mg/mL every day (QD) administered SC.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries